RS-2024-00460284

DM5167 Phase 1 Clinical Trial of a 2nd Generation PARP-1 Selective Inhibitor

Digmbio

DIGMBIO

ONCOLOGY | **Phase 1**

Product Type	Small Molecule
Indication	PARP inhibitors are approved for treating cancers associated with BRCA mutations or HRD, including ovarian, breast, prostate, and pancreatic cancers.
Target	PARP-1 selective inhibitor
MoA(Mechanism of Action)	When PARP-1 is inhibited, cancer cells with defective DNA repair mechanisms, such as those with BRCA mutations or homologous recombination deficiencies (HRD), lose the ability to repair DNA damage effectively. This leads to the accumulation of unrepaired DNA damage, ultimately resulting in cell death
Competitiveness	Preclinical data demonstrate that DM5167 surpasses first-generation PARP inhibitors and AstraZeneca's Saruparib across all parameters, particularly in its differentiated toxicity profile and superior blood-brain barrier (BBB) penetration, highlighting its potential to be best-in-class.
Development Stage	DM5167 is currently in Phase 1 clinical trials in cancer patients, following approval by the Korea FDA.
Route of Administration	Oral administration (PO)

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund